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Background:  Chronic critical limb ischemia (CLI) is an increasing cause of morbidity and mortality in patients with peripheral arterial 
disease (PAD). Despite the marked advances in surgical and endovascular techniques, a substantial part of patients with CLI is not eligible for 
revascularization. We sought to evaluate the effect of autologous bone marrow mononuclear cells (BM-MNCs) on symptoms and perfusion indices in 
patients with end-stage CLI.
Material and Methods:  Bone marrow from cristae iliacae was harvested in analgosedation in symptomatic CLI patients and mononuclear cells 
were isolated by the Ficoll™ density gradient method. BM-MNCs were implanted into the index leg by means of combined intraarterial and multiple 
intramuscular injections. Pain, total walking distance, ankle-brachial index (ABI) and transcutaneous O2-pressure (TcPO2) were recorded at baseline 
and at 6 weeks after the procedure.
Results:  A total of 16 patients (4 female, mean age: 61±14) were treated. From the BM-aspirate (317±61 m), a total of 4.9±2.4 x10^8 
mononuclear cells were isolated. Results of ABI, TcPO2, total pain-free walking distance and pain score at baseline and at 6 weeks follow-up are 
presented in the table.
Conclusion: Autologous BM-MNC therapy in end-stage PAD patients reduces symptoms by improving perfusion indices. If this beneficial effect can 
be confirmed by randomized control trials, BM-MNC therapy could serve as an additive therapeutic option for end-stage PAD patients.
Table:
Parameter Baseline 6 weeks after BM-MNC therapy P-value
ABI 0.43±0.12 0.56±0.11 <0.01
TcPO2 14±8 35±10 <0.01
Total walking distance 52±45 358±360 <0.01
Pain Score 5.1±2.2 2.7±2.5 <0.01
